Comprehensive microRNA profiling of prostate cancer

Journal of Cancer

Volumn 4, Issue 5, 2013, Pages 350-357

  Walter, Beatriz A ^a   Valera, Vladimir A ^a   Pinto, Peter A ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; microRNA; Prostate Cancer

Indexed keywords

MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 125; MICRORNA 126; MICRORNA 138; MICRORNA 143; MICRORNA 144; MICRORNA 146B; MICRORNA 148; MICRORNA 184; MICRORNA 193; MICRORNA 198; MICRORNA 212; MICRORNA 215; MICRORNA 222; MICRORNA 27; MICRORNA 29B; MICRORNA 335; MICRORNA 34; MICRORNA 34C; MICRORNA 373; MICRORNA 9; MICRORNA 92; MICRORNA 96; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE CANCER; UPREGULATION;

EID: 84883027905     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6394     Document Type: Article

References (25)

1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
2. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-400.
3. Lilleby W, Torlakovic G, Torlakovic E, Skovlund E, Fossa SD. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy. Cancer 2001;92:311-9.
4. Spires SE, Cibull ML, Wood DP, Jr., Miller S, Spires SM, Banks ER. Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 1994;118:705-8.
5. Roach M, 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7.
6. Lughezzani G, Gallina A, Larcher A, et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int 2012.
7. Cerovic S, Brajuskovic G. [Forty years' use of Gleason grading in the diagnostics and treatment of prostate cancer]. Vojnosanit Pregl 2006;63:1049-53.
8. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-6.
9. Bazinet M, Hamdy SM, Begin LR, Stephenson RA, Fair WR. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate 1992;20:311-26.
10. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011;38:724-33.
11. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn 2011;11:813-27.
12. Hassan O, Ahmad A, Sethi S, Sarkar FH. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol 2012;5:9.
13. Gordanpour A, Nam RK, Sugar L, Seth A. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis 2012.
14. Oberg AL, French AJ, Sarver AL, et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One 2011;6:e20465.
15. Ferracin M, Querzoli P, Calin GA, Negrini M. MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol 2011;38:764-75.
16. Song T, Xia W, Shao N, et al. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 2010;11:905-11.
17. Enkelmann A, Heinzelmann J, von Eggeling F, et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 2011;137:751-9.
18. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
19. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
20. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 2010;42:363-9.
21. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93.
22. Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009;16:206-16.
23. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010;7:286-97.
24. Selth LA, Tilley WD, Butler LM. Circulating microRNAs -macro-utility as markers of prostate cancer? Endocr Relat Cancer 2012.
25. Gandellini P, Profumo V, Casamichele A, et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012.